Drugs / COSFROVIXIMAB
COSFROVIXIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02389192 | Mar 2015 → Dec 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COSFROVIXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990001 ↗ |
| Known as | 13C6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990001 ↗ |
| Known as | c13C6-FR1 | “ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes” NCT02389192 ↗ |
| Known as | Cosfroviximab component of mb-003 c13c6-fr1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990001 ↗ |
| Known as | Cosfroviximab component of zmapp c13c6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990001 ↗ |
| Known as | Cosfroviximab component of zmapp c13c6-fr1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990001 ↗ |
| Known as | Zmapp | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990001 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3990001 ↗ |